This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

No Easy Fix for Pfizer

A mixture of disappointing deals, poor marketing and bad luck, unfolding during a plague of patent expirations, has put long-term investors in Pfizer (PFE - Get Report) in a bind and analysts in a surly mood.

Over the past five years, Pfizer's stock is down 28%, lagging both the S&P 500-stock index and the Amex Pharmaceutical Index, which contains Big Pharma stocks, including Pfizer.

Even under Jeffrey Kindler, who has been restructuring the company since becoming CEO in July 2006, shares are off 15% in the last 12 months.

While analysts have been grumbling, however, drug-industry management experts are more optimistic -- or at least less anxious -- about Pfizer's turnaround prospects, given its financial strength and still-strong credit rating.

"It's fixable. They have tons of cash sitting in the bank," says Prof. Mahmud Hassan, director of the pharmaceutical MBA program at Rutgers, the state university of New Jersey, who tells investors to be patient.

"Most investors are myopic," he says. "Look at the Vioxx situation. When people saw Vioxx wasn't as big a problem as they thought, Merck's (MRK - Get Report) stock picked up."

Merck and Schering-Plough (SGP), which is cleaning up past regulatory problems, have had more dramatic setbacks than Pfizer, but they have since become more attractive to Wall Street.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIIB $286.55 -1.31%
NKTR $11.41 2.15%
MRK $51.23 2.17%
NBIX $42.72 -3.06%
PFE $33.48 1.21%


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs